💨 Abstract

The NHS will introduce highly sensitive blood tests to detect cancer cell fragments (ctDNA) in patients with breast or lung cancer, enabling quicker access to personalized treatment. These "liquid biopsies" could streamline diagnosis and guide treatment, potentially reducing the need for invasive biopsies and scans. England is the first country to widely roll out this technology, which aims to improve patient outcomes and save costs.

Courtesy: Sam Blanchard